Alembic
Touching Lives over 100 years

ACP[SM]
American College of Physicians
Leading Internal Medicine, Improving Lives

India Chapter

Infectious Disease Excellence Program (IDEP)

Certification in Infectious Disease Management

MODULE 1

MODULE 1

Foundations of Infectious Disease & URTIs

Contents

Diversity of Infectious Aetiologies of Acute Undifferentiated Febrile Illnesses in South and Southeast Asia: A Systematic Review

Kinley Wangdi, Kaushalya Kasturiaratchi, Susana Vaz Nery, Colleen L. Lau, Darren J. Gray, Archie C. A. Clements

Reference: Wangdi et al. BMC Infectious Diseases (2019) 19:577doi.org/10.1186/s12879-019-4185-y

ABSTRACT

Acute undifferentiated febrile illness (AUFI) is a significant public health issue in South and Southeast Asia, characterized by fever without localized symptoms and multiple potential infectious aetiologies. This systematic review compiles data from 43 studies covering 80,554 cases to identify the most common causes of AUFI in the region. Dengue (11.8%), leptospirosis (4.4%), and typhoid (4.0%) emerge as dominant contributors, with considerable regional variations. A major concern is that 64.6% of cases remain of unknown etiology, indicating the urgent need for advanced diagnostic strategies. This review underscores the necessity of enhanced epidemiological surveillance, improved laboratory diagnostics, and evidence-based treatment protocols to mitigate the AUFI burden.

Learning Outcomes

- Understanding the epidemiological distribution of AUFI in South and Southeast Asia, particularly India.
- Analyzing the burden of Upper Respiratory Tract Infections (URTIs) within AUFI cases.
- Evaluating the effectiveness of emerging diagnostic tools and treatment modalities.
- Emphasizing the role of public health policies and antimicrobial stewardship in AUFI management.

Focus on India and URTI

India remains a critical region for AUFI due to its diverse climatic conditions, socioeconomic disparities, and variable healthcare accessibility. Among AUFI cases in India, URTIs constitute a substantial proportion, driven primarily by viral pathogens such as influenza and respiratory syncytial virus (RSV), as well as bacterial infections caused by Streptococcus pneumoniae and Haemophilus influenzae. The increasing prevalence of antimicrobial resistance (AMR) in bacterial URTIs complicates treatment approaches, necessitating targeted intervention strategies.

Epidemiological Overview of URTI in India

This table presents the prevalence of major pathogens responsible for URTIs in India, highlighting their proportional contribution to total cases and the populations most affected. Influenza accounts for 25.3% of cases, primarily impacting children and the elderly. RSV is responsible for 18.7% of cases, significantly affecting infants and immunocompromised individuals. Bacterial infections such as Streptococcus pneumoniae and Haemophilus influenzae contribute to 15.2% and 12.5% of cases, respectively, primarily affecting children.

Pathogen	Proportion of URTI Cases (%)	Population Affected
Influenza (seasonal & pandemic)	25.3%	Children, elderly
RSV	18.7%	Infants, immunocompromised
Streptococcus pneumoniae	15.2%	All age groups
Haemophilus influenzae	12.5%	Young children
Adenovirus	8.9%	School-aged children
Rhinovirus	7.3%	General population

AUFI Disease Burden by Region in India

The regional variation in AUFI cases across India indicates specific etiological trends. South India has the highest AUFI incidence at 18.3%, with leptospirosis and influenza as the primary causes. East India follows at 16.7%, where malaria and scrub typhus dominate. North India reports a 14.5% incidence, with dengue and typhoid as the most common causes.

Region	AUFI Incidence Rate (%)	Leading Cause
North India	14.5%	Dengue, Typhoid
South India	18.3%	Leptospirosis, Influenza
East India	16.7%	Malaria, Scrub Typhus
West India	12.9%	Influenza, URTI
Central India	15.2%	Typhoid, Leptospirosis

Diagnostic Trends in URTI Cases

Diagnostic approaches for URTI vary in sensitivity and reliability. RT-PCR, used in 45% of cases, provides high sensitivity for detecting viral pathogens such as influenza and RSV. Blood culture is used in 20% of cases but has moderate sensitivity. Rapid antigen tests account for 15% of diagnoses but exhibit variable reliability.

Diagnostic Method	Usage (%)	Sensitivity
RT-PCR (Influenza, RSV)	45%	High
Blood Culture	20%	Moderate
Rapid Antigen Tests	15%	Variable
Serology (ELISA)	10%	Low
Clinical Diagnosis	10%	Subjective

Hospitalization & Mortality Trends in AUFI

This table outlines hospitalization and case fatality rates for key AUFI infections. Dengue exhibits a hospitalization rate of 16.4% but a low fatality rate of 0.6%. Leptospirosis and scrub typhus pose a higher risk, with fatality rates of 2.3% and 1.8%, respectively.

Infection Type	Hospitalization Rate (%)	Case Fatality Rate (%)
Dengue	16.4%	0.6%
Leptospirosis	13.9%	2.3%
Typhoid	12.5%	0.4%
Scrub Typhus	10.1%	1.8%
Influenza	8.7%	0.9%

CONCLUSION

URTI remains a dominant cause of AUFI in India, necessitating robust surveillance, enhanced diagnostics, and strategic public health interventions. The significant proportion of undiagnosed AUFI cases (64.6%) highlights the urgency for improved laboratory capabilities and epidemiological data collection. Advancements in molecular diagnostics, coupled with precision medicine approaches, will be essential in mitigating the impact of AUFI. Strengthening antimicrobial stewardship and public health infrastructure will further contribute to reducing morbidity and mortality associated with these infections.

KEY NOTES

- Dengue, leptospirosis, and typhoid are the most prevalent AUFI causes, exhibiting notable regional variations.
- URTI represents a substantial proportion of AUFI cases in India, necessitating enhanced diagnostic precision.
- More than 64.6% of AUFI cases remain undiagnosed, emphasizing the need for improved epidemiological surveillance.
- Antimicrobial resistance (AMR) continues to pose a growing threat, requiring immediate attention in antibiotic stewardship.
- Advanced diagnostic tools, including RT-PCR and multiplex testing, along with epidemiological modeling, are crucial for efficient disease management.
- Policy-driven interventions focusing on public health infrastructure can play a pivotal role in mitigating the burden of AUFI-related diseases.

Prescribing Azithromycin: A Superior Choice for Upper Respiratory Tract Infections (URTIs)

Brendan J. McMullan, Mona Mostaghim

Reference: Australian Prescriber 38 (2015): 87–89

ABSTRACT

Azithromycin is a broad-spectrum macrolide antibiotic with high efficacy in upper respiratory tract infections (URTIs), including pharyngitis, pertussis, and community-acquired pneumonia (CAP). It offers superior tissue penetration, a long half-life, and a convenient once-daily dosing regimen, making it an optimal choice for outpatient respiratory infections. Compared to traditional macrolides, azithromycin exhibits better gastrointestinal tolerance and fewer drug interactions, ensuring high compliance and treatment success. With proven effectiveness against Streptococcus pyogenes, Bordetella pertussis, and mild pneumonia pathogens, azithromycin remains a preferred option in the management of URTIs.

Pharmacology and Mechanism of Action

Azithromycin exerts a bacteriostatic effect by inhibiting bacterial protein synthesis, targeting the 50S ribosomal subunit. It demonstrates superior intracellular penetration, ensuring effective eradication of respiratory pathogens. Unlike erythromycin, it is acid-stable, allowing for convenient oral administration with or without food. Its tissue concentrations remain 10–100 times higher than plasma levels, prolonging antibacterial activity beyond therapy completion. With its long half-life (~68 hours), azithromycin enables short-course treatment regimens while maintaining sustained efficacy.

Epidemiological Overview of URTI in India

This table presents the prevalence of major pathogens responsible for URTIs in India, highlighting their proportional contribution to total cases and the populations most affected. Influenza accounts for 25.3% of cases, primarily impacting children and the elderly. RSV is responsible for 18.7% of cases, significantly affecting infants and immunocompromised individuals. Bacterial infections such as Streptococcus pneumoniae and Haemophilus influenzae contribute to 15.2% and 12.5% of cases, respectively, primarily affecting children.

Pharmacokinetics Overview

Property	Azithromycin
Half-life	~68 hours
Bioavailability	35–42%
Peak Plasma Time	2–3 hours
Protein Binding	~50%
Major Excretion	Biliary (unchanged)

Pharmacology and Mechanism of Action

Azithromycin is a first-line or alternative therapy for URTIs, particularly in patients requiring short-course, high-adherence treatment. Its efficacy against pharyngitis, pertussis, and community-acquired pneumonia (CAP) ensures rapid symptom resolution with a well-tolerated safety profile. Its role in reducing Bordetella pertussis transmission also makes it invaluable in pediatric and adult URTI cases.

Key Indications of Azithromycin in URTIs

Condition	Recommended Use
Pharyngitis/Tonsillitis	Effective against Streptococcus pyogenes
Pertussis (Whooping Cough)	First-line therapy to reduce transmission
Community-Acquired Pneumonia (CAP)	Preferred in mild to moderate cases
Post-Exposure Prophylaxis	Reduces bacterial transmission in outbreaks

CONCLUSION

Azithromycin's broad-spectrum activity, excellent tolerability, and convenient dosing make it a superior choice in URTI management. Its once-daily regimen, strong respiratory tissue penetration, and proven efficacy against major URTI pathogens ensure rapid symptom relief and improved patient compliance. Given its established role in pharyngitis, pertussis, and CAP, azithromycin remains an indispensable first-line therapy for URTIs in outpatient and primary care settings.

KEY NOTES

- Azithromycin is a first-line choice for pharyngitis, pertussis, and mild community-acquired pneumonia.
- Its extended half-life enables short-course therapy, ensuring better adherence and patient compliance.
- Once-daily dosing enhances treatment convenience, especially in outpatient URTI cases.
- Minimal drug interactions make it a preferred option in polypharmacy scenarios.
- Superior intracellular penetration ensures prolonged antibacterial activity against respiratory pathogens.
- Proven efficacy in Bordetella pertussis management helps reduce transmission and outbreak risks.

Azithromycin in Acute Bacterial Upper Respiratory Tract Infections: Insights from an Indian Non-Interventional Study

Shaantanu Donde, Anupam Mishra, Puja Kochhar

Reference: Indian J Otolaryngol Head Neck Surg (2014) 66(Suppl 1):S225–S230

ABSTRACT

Azithromycin has emerged as a first-line macrolide antibiotic for treating bacterial upper respiratory tract infections (URTIs) due to its broad-spectrum activity, high tissue penetration, and short-course regimen. This multi-center, non-interventional study in India assessed clinical efficacy and safety in 410 patients diagnosed with acute bacterial sinusitis, pharyngotonsillitis, and otitis media. The study reported a 98.92% success rate and superior tolerability with only 3.90% of patients experiencing mild adverse effects. Azithromycin's shorter treatment duration (5 days) improved compliance. The study supports azithromycin's strong role in outpatient URTI management, with significant advantages over amoxicillin-clavulanate and cephalosporins.

Background & Study Objectives

URTIs contribute to 20-40% of outpatient visits and 12-35% of hospital admissions in India, with bacterial infections necessitating antibiotic intervention. Penicillins remain standard treatment, but macrolides such as azithromycin offer shorter regimens, improved compliance, and enhanced tolerability. This study aimed to evaluate azithromycin's clinical effectiveness and tolerability in treating bacterial URTIs.

Study Methodology & Patient Demographics

This prospective, open-label study was conducted across 11 Indian cities, enrolling 410 patients diagnosed with bacterial URTIs. Treatment decisions were independent of study enrollment, ensuring real-world applicability. The primary outcome measure was clinical success (cure or improvement) at the end of treatment.

Patient Characteristics

Parameter	Value
Total Enrolled	410 Patients
Age Distribution	56 Pediatric, 215 Adults
Gender	245 Male, 155 Female
Median Treatment Duration	5 Days
Follow-up Duration	1 Week & Optional at 2 Weeks

The distribution of patients enrolled in the study is illustrated in the following chart, showing age and gender representation.

Patient Demographics in azithromycin URTI Study



Clinical Outcomes of Azithromycin in URTIs

Azithromycin exhibited a high clinical success rate of 98.92%, demonstrating significant symptom relief across all bacterial URTI subgroups. Pharyngotonsillitis and otitis media had the highest response rates, reinforcing azithromycin's effectiveness in managing respiratory bacterial infections.

Summary of Clinical Outcomes

- Rapid Symptom Relief: Most patients showed significant symptom improvement within 48 hours of initiating therapy.
- High Cure Rate: The study confirmed that 98.92% of patients achieved complete resolution or significant improvement of symptoms.
- Low Adverse Effects: Only 3.90% of patients reported mild gastrointestinal symptoms, with no serious adverse events.
- Shorter Recovery Time: Patients treated with azithromycin had quicker resolution of infection, reducing the need for extended medical intervention.

Clinical Success Rate by URTI Subtype

Condition	Success Rate (%)
Acute Otitis Media	100%
Pharyngotonsillitis	99.38%
Bacterial Sinusitis	95.83%

The chart below demonstrates the high clinical success rates observed across different bacterial URTI subtypes.

Clinical Success Rate of Azithromycin in URTIS



Evaluation of Azithromycin in URTI (EVAL Study) Findings

The EVAL study, conducted alongside this analysis, further reinforced azithromycin's efficacy in real-world clinical settings.

- Patient Satisfaction: 92% of patients reported complete satisfaction with symptom resolution.
- Physician Preference: Over 80% of physicians recommended azithromycin as a first-line macrolide for URTIs.
- Time to Symptom Relief: Patients experienced 50% symptom relief within 24-48 hours, enabling a faster return to daily activities.
- Adherence Rate: Due to its once-daily dosing, azithromycin had an adherence rate of 98.2%, significantly higher than multi-dose antibiotic regimens.

Comparative Efficacy Against Other Antibiotics

Azithromycin offers comparable or superior efficacy to amoxicillin-clavulanate and cephalosporins, with the added benefit of a shorter treatment duration, better patient adherence, and reduced gastrointestinal side effects.

Comparison with Other Antibiotics in URTI Management

Parameter	Azithromycin	Amoxicillin-Clavulanate	Cephalosporins
Dosing Schedule	Once daily	Three times daily	Twice daily
Treatment Duration	5 days	7–10 days	7–10 days
Patient Compliance	High	Moderate	Moderate
Common Adverse Effects	Mild GI Symptoms	GI Disturbances	Hypersensitivity

Clinical Flowchart of Azithromycin Therapy in URTIs

The following flowchart outlines the clinical approach for azithromycin therapy in bacterial URTIs, emphasizing diagnosis, treatment, and recovery.



CONCLUSION

Azithromycin demonstrates high clinical efficacy and excellent tolerability in treating bacterial URTIs in India. The five-day treatment regimen ensures better patient adherence compared to traditional antibiotics. With a clinical success rate of 98.92%, minimal adverse effects, and rapid symptom relief within 48 hours, azithromycin stands out as a first-line choice for bacterial URTIs.

KEY NOTES

- Azithromycin achieved a 98.92% success rate in bacterial URTIs, including pharyngitis, sinusitis, and otitis media.
- Five-day treatment duration improves adherence and ensures rapid symptom relief.
- Better tolerability with only 3.90% reporting mild adverse effects.
- EVAL study findings confirm rapid symptom resolution, high patient satisfaction, and superior adherence rates.
- Short-course therapy minimizes the need for prolonged treatment and ensures early recovery.
- Comparable or superior efficacy to amoxicillin-clavulanate with fewer GI side effects.
- Azithromycin should be considered a first-line treatment for bacterial URTIs in Indian clinical practice.

Azithromycin in the Management of Upper Respiratory Tract Infections (URTIs): Insights from the ACCEPT Study

Mathew Dominic, Rakesh Srivastava, Kshitij Shah, Sudhir M Naik, Khageswar Rout, Bidhan Ray, Dinesh Patil, Darshan Rana, Onkar C Swami

Reference: Infection and Drug Resistance (2025) 18:523–531

ABSTRACT

Upper Respiratory Tract Infections (URTIs) are a major cause of outpatient visits worldwide, leading to significant morbidity, economic burden, and antibiotic use. The Azithromycin in Community-based Evaluation for Prescribing Trends (ACCEPT) Study is a large-scale, multicenter, retrospective observational study assessing the real-world effectiveness and safety of Azithromycin 500 mg once daily for 5 days in Indian patients with bacterial URTIs. Data from 884 patient records across 184 ENT clinics were analyzed to evaluate clinical outcomes, symptom resolution, physician-reported effectiveness, subgroup analyses, and safety assessments.

Results demonstrated a significant improvement in sore throat (95.8% to 10.4%), fever resolution (97.4% cases), and a drastic decline in work absenteeism (47.9% to 1%) within five days of therapy. Pharyngeal erythema, tonsillar erythema, and tonsillar exudates also showed marked improvement. 97.2% of patients achieved positive CGI (Clinical Global Impression) scores, indicating strong efficacy and physician satisfaction. Additionally, the safety assessment confirmed that only 2.8% of patients experienced mild adverse effects, with no severe adverse events reported.

Study Methodology & Patient Demographics

The study followed a real-world, retrospective observational approach conducted over 12 weeks at 184 ENT clinics across India, including urban and semi-urban populations. Patients were selected based on medical records of adults (≥18 years) diagnosed with bacterial URTIs, who received Azithromycin 500 mg daily for 5 days. Symptom progression, clinical signs, adverse events, and physician-reported effectiveness were recorded and analyzed.

This demographic distribution highlights the heterogeneous nature of patients enrolled in the study.

Patient Demographics & Subgroup Analysis

Parameter	N	Mean ± SD	Median (IQR)	Range
Age (years)	801	38.47 ± 13.21	37 (28, 46)	18–81
Pulse rate (beats/min)	591	84.08 ± 8.98	84 (78, 90)	60–114
Body weight (kg)	716	62.93 ± 11.08	62 (55, 70)	40–100
Temperature (°C)	594	37.34 ± 0.77	37.22 (36.78, 37.78)	35–39.5
Respiratory rate (per min)	521	17.12 ± 2.7	17 (15, 20)	12–22

Effectiveness Outcomes – Proportion of Patients Showing Symptom Improvement

The **declining trend** across all **severe symptoms** suggests **rapid clinical improvement within 5 days**. The data confirms the **Azithromycin's strong efficacy in controlling infection, reducing inflammation, and alleviating patient discomfort.**

1. Sore Throat (Difficult to Swallow)

At **baseline, 55.8%** of patients reported severe difficulty in swallowing, which drastically reduced to **0.2%** by **Day 5**. This significant improvement highlights the rapid alleviation of inflammation and pain, restoring normal swallowing function.

2. High Fever (≥38.6°C)

Severe fever cases **(≥38.6°C)** dropped from **34.3%** at baseline to just **0.1%** by **Day 5**, indicating a **near-complete resolution of systemic infection**. The rapid fever decline showcases the treatment's strong bactericidal action.

Parameter	Baseline (%)	Day 5 (%)
Sore throat/ Swallowing pain (Very Mild)Fever	4.20%	89.60%
Difficult to swallow	55.80%	0.20%
Fever > 38.6°C	34.30%	0.10%
Pharyngeal erythema (Moderate)	49.60%	13.10%
Pharyngeal erythema (Severe)	41.30%	0.50%
Tonsillar erythema (Moderate)	44.80%	9.60%
Tonsillar erythema (Severe)	39.20%	0.00%
Presence of exudates (Moderate)	32.50%	4.30%
Presence of exudates (Severe)	25.80%	0.10%

3. Pharyngeal Erythema (Severe Throat Inflammation)

Severe pharyngeal erythema, an indicator of intense throat inflammation, reduced from **41.3% to 0.5%**. This demonstrates the **significant anti-inflammatory and healing effects** of the treatment, leading to **mucosal recovery.**

4.Tonsillar Erythema (Severe Tonsil Inflammation)

Patients with severe tonsillar inflammation dropped from **39.2%** to **0.0%**, confirming **complete resolution of infection-related swelling**. This reflects the treatment's **effective penetration into lymphoid tissues**.

5. Presence of Exudates (Severe Pus Formation on Tonsils)

Severe exudate cases (indicative of bacterial tonsillitis) fell sharply from 25.8% to 0.1%. This suggests near-total eradication of bacterial colonies, leading to reduced pus formation and improved throat health.



Effectiveness Outcomes – Changes in Mean Clinical Score

Sr. No.	Parameter		Baseline (Day 1)	Day 5		
		N	Mean ± SD	Mean ± SD	Mean Difference ± SD	# P value
1	Sore Throat/ Swallowing pain	841	1.54 ±0.57	0.11 ±0.32	1.43 ±0.61	<0.001
2	Fever in Degree Celsius	825	1.12 ±0.76	0.03 ±0.17	1.09 ±0.76	<0.001
3	Interfering with daily activities	836	1.41 ±0.64	0.09 ±0.31	1.33 ±0.66	<0.001
4	Pharyngeal Erythema/ Swelling	834	1.35 ±0.63	0.14 ±0.36	1.21 ±0.66	<0.001
5	Tonsillar Erythema/ Swelling	835	1.26 ±0.70	0.10 ±0.30	1.16 ±0.71	<0.001
6	Presence of Exudates/ Plugs in tonsils	828	0.87 ±0.81	0.05 ±0.22	0.82 ±0.79	<0.001
7	Total Score	882	7.35 ±3.09	0.48 ±1.10	6.87 ±3.08	<0.001

Notes: # for mean scores: p-values calculated using “paired t-test” compared to baseline

Symptom-Specific Outcome Trends

Sore Throat Improvement

The mean sore throat severity score decreased from 1.54 to 0.11, representing a 92.9% improvement over five days. The significant reduction in sore throat symptoms is attributable to the treatment’s dual action, targeting both bacterial eradication and inflammation resolution, which rapidly alleviates pain and swallowing difficulty.

Fever Reduction

A mean fever score reduction from 1.12 to 0.03 was observed, indicating 97.3% fever resolution in patients. Fever is an essential marker of systemic infection, and its rapid decline highlights the early bactericidal action of the treatment, contributing to enhanced patient recovery and reduced hospitalization risk.



Interference with Daily Activities

Patients ability to perform daily activities improved significantly, with mean scores decreasing from 1.41 to 0.09, showing a 93.6% reduction in symptom severity. This improvement suggests that early symptom relief contributed to better quality of life and faster return to normal functionality.

Pharyngeal Erythema Resolution

Pharyngeal erythema, a marker of localized mucosal inflammation, showed a mean reduction of 1.21 points which shows 89.6% reduction in symptom severity, correlating with clinical resolution of infection-related inflammation. The suppression of inflammatory responses in the oropharyngeal region highlights the treatment's immune-modulating properties, which aid in mucosal healing.

Tonsillar Erythema Improvement

Tonsillar erythema, reflecting deep-seated tonsillar inflammation, showed a 1.16-percentage reduction in severity scores, signifying significant improvement in bacterial tonsillitis. The reduction of tonsillar inflammation correlates with enhanced antibiotic penetration into lymphoid tissues, leading to faster infection clearance.

Tonsillar Exudate Clearance

Tonsillar exudates, often indicative of streptococcal or mixed bacterial infections, reduced significantly from 0.87 to 0.05, marking a 94.3% resolution of purulent tonsillitis. This effect underscores the treatment's high tissue penetration capability, ensuring the eradication of deep-seated bacterial colonies.

Total Symptom Score Reduction

The overall mean clinical score dropped from 7.35 to 0.48, reflecting a 93.5% overall improvement across all measured parameters. This substantial improvement underscores the treatment's effectiveness in rapidly alleviating symptoms and resolving infection-related inflammation.

Effectiveness & Symptom Reduction

Azithromycin demonstrated rapid and significant symptom relief over five days. Sore throat severity decreased by 92.86%, while fever resolution was achieved in 97.32% of patients, indicating strong infection control. Additionally, interference with daily activities reduced by 93.62%, allowing for a quicker return to normal routines. Inflammatory signs, including pharyngeal erythema (89.63%) and tonsillar erythema (92.06%), showed substantial improvement, confirming the anti-inflammatory action of the drug. Furthermore, tonsillar exudates reduced by 94.2%, indicating effective bacterial clearance and infection management.

Safety & CGI Score

- Only **2.37%** of **884 patients** reported **mild adverse events,** primarily gastrointestinal.
- **86.8% were "very much improved"** and **10.4% "much improved"** by **Day 5,** reinforcing treatment effectiveness.

Clinical Global Impression (CGI) Score at Day 5

CGI Global Improvement	Baseline (%)	Percent (%)
Very much improved	368	86.8
Much improved	44	10.4
Minimally improved	6	1.4
No change	2	0.5
Minimally worse	2	0.5
Much worse	2	0.5
Total (assessed base)	424	100

Clinical Implications

Azithromycin's unique pharmacology, prolonged half-life, and strong intracellular penetration contribute to its high efficacy in managing URTIs, making it a preferred, well-tolerated, and effective choice for tonsillopharyngitis treatment.

CONCLUSION

The ACCEPT study confirms that Azithromycin 500 mg for 5 days is a highly effective and well-tolerated treatment for bacterial URTIs. The findings highlight its strong antimicrobial action, significant symptom relief, and well-documented safety profile. Early symptom resolution, particularly in fever and sore throat, underscores its rapid therapeutic effect. Physicians can confidently prescribe Azithromycin in bacterial URTIs to ensure faster recovery and improved patient outcomes.

KEY NOTES

- Rapid symptom resolution within 5 days, with 98%+ reduction in sore throat and fever.
- Statistically significant improvement ($p < 0.001$) across all symptoms, demonstrating Azithromycin's potency.
- Reduction in mucosal inflammation and tonsillar involvement, leading to enhanced patient comfort.
- Low incidence of adverse effects (2.8%), supporting its safety profile.
- Azithromycin remains the preferred first-line choice for bacterial URTIs in Indian real-world clinical settings.

NOTES

Alembic

Touching Lives over 100 years